ERBB2 and neoplasm: Therefore, a possibility of identifying a subgroup of TNBC patients who may benefit from new anti-HER2 therapies is particularly promising, especially given that these tumours are usually associated with poor prognosis due to the scarcity of effective therapeutic options [42–45].